Figure 7
MPT0E028 in combination with erlotinib suppresses the growth of EGFR inhibitor-resistant tumor xenografts in vivo. (a) Kaplan–Meier survival curves are shown for each treatment group. Survival in the co-treated group was significantly extended (P<0.05) compared with the control groups. The log-rank test was used to calculate P-values. (b) Mice bearing established A549 tumors (∼100 mm3) were dosed by gavage with vehicle (Veh), MPT0E028 (M) 50 or 100 mg/kg QD, erlotinib (E) at 50 mg/kg QD, or MPT0E028 plus erlotinib at 50+50 mg/kg QD or 50+100 mg/kg QD (combination). Eight mice per group were used in the xenograft experiment. The tumor volumes of mice were measured. Symbols: *P<0.05, **P<0.01, and ***P<0.001 for comparisons with MPT0E028 alone. (c) The drug treatments did not cause significant body weight loss in the tested animals. (d) Effects of treatments on intratumoral biomarkers of drug activity in A549 xenograft tumors. Athymic nude mice bearing established subcutaneous (s.c.) A549 xenograft tumors were randomized to six groups (n=8 per group) that received the indicated treatments by gavage. The experimental details are described in the Materials and Methods section
